News coverage about Kala Pharmaceuticals (NASDAQ:KALA) has trended somewhat positive this week, according to Accern. The research group identifies negative and positive media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Kala Pharmaceuticals earned a news sentiment score of 0.23 on Accern’s scale. Accern also assigned media stories about the company an impact score of 44.6587389795431 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Shares of Kala Pharmaceuticals (NASDAQ KALA) traded up $1.14 during midday trading on Monday, reaching $13.61. The company’s stock had a trading volume of 370,913 shares, compared to its average volume of 517,335. The stock has a market capitalization of $329.73 and a price-to-earnings ratio of -7.48. The company has a current ratio of 11.00, a quick ratio of 11.00 and a debt-to-equity ratio of 0.14. Kala Pharmaceuticals has a 52 week low of $11.81 and a 52 week high of $26.75.
Several analysts have recently commented on the stock. BidaskClub lowered shares of Kala Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday. Wells Fargo & Co reissued an “outperform” rating and issued a $19.00 target price (down previously from $24.00) on shares of Kala Pharmaceuticals in a research report on Thursday, January 25th. They noted that the move was a valuation call. JPMorgan Chase & Co. set a $35.00 target price on Kala Pharmaceuticals and gave the company a “buy” rating in a research report on Sunday, November 19th. Wedbush reissued a “buy” rating and issued a $46.00 target price on shares of Kala Pharmaceuticals in a research report on Thursday, November 30th. Finally, Zacks Investment Research lowered Kala Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, October 17th. Two investment analysts have rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $35.80.
In other Kala Pharmaceuticals news, major shareholder Orbimed Advisors Llc purchased 25,000 shares of the company’s stock in a transaction on Thursday, February 8th. The stock was acquired at an average price of $12.93 per share, for a total transaction of $323,250.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In the last 90 days, insiders acquired 1,108,150 shares of company stock valued at $15,772,394.
COPYRIGHT VIOLATION NOTICE: This story was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this story on another domain, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this story can be viewed at https://www.dispatchtribunal.com/2018/02/13/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-kala-pharmaceuticals-kala-share-price.html.
About Kala Pharmaceuticals
Kala Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics through its nanoparticle-based Mucus Penetrating Particles, or MPP, technology. The Company’s initial focus is on the treatment of eye diseases. The Company’s product candidate includes KPI-121 1%, KPI-121 0.25% and MPP rTKI Program.
Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.